MedImmune Announces Research Collaboration with UC SanFrancisco - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

MedImmune Announces Research Collaboration with UC SanFrancisco

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 3
MedImmune, the biologics research and development arm of AstraZeneca, has entered into a three-year collaboration with the Clinical and Translational Science Institute (CTSI) at the University of California, SanFrancisco (UCSF). The collaboration will focus on CTSI’s Catalyst Awards program, which solicits applications from University scientists who wish to move their translational research into product development.

This marks the first industrial partnership for CTSI’s Catalyst Awards program’s therapeutic track, which focuses specifically on discovery and development of patient treatment options. The collaboration will benefit both MedImmune’s biologics and AstraZeneca’s small molecule portfolios and will call for proposals in therapeutic areas of interest to MedImmune and AstraZeneca, including cardiovascular and metabolic disease, oncology, respiratory, inflammation and autoimmunity, neuroscience and infectious disease.

Financial terms around the collaboration were not disclosed.

Source: MedImmune

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here